Mikkael Sekeres, MD, on MDS Classification System Updates

In this episode of “Blood Cancer Talks,” the hosts discuss how to manage low-risk myelodysplastic syndromes (MDS) with Mikkael Sekeres, MD, of the University of Miami Sylvester Comprehensive Cancer Center.

They discuss the International Consensus Classification of Myeloid Neoplasms and Acute Leukemias, updates to the World Health Organization classification system that impact MDS, and the Molecular International Prognostic Scoring System. They also highlight data from studies evaluating romiplostim, lenalidomide, luspatercept, and other therapies in MDS.

Dr. Sekeres also speaks about his time on the US Food and Drug Administration (FDA) Oncologic Drugs Advisory Committee, and his latest book, titled “Drugs and the FDA.”